menu search

Creso pharma completes integration of creso impactive ltd assets as it continues to broaden us horizons

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has completed the integration of Creso ImpACTIVE Ltd's assets into its product portfolio in a move that shoul...

November 14, 2021, 7:51 pm

Creso pharma completes integration of creso impactive ltd assets as it continues to broaden us horizons

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has completed the integration of Creso ImpACTIVE Ltd's assets into its product portfolio in a move that shoul...

November 14, 2021, 7:51 pm

Creso pharma completes integration of creso impactive ltd assets as it continues to broaden us horizons

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has completed the integration of Creso ImpACTIVE Ltd's assets into its product portfolio in a move that shoul...

November 14, 2021, 7:51 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine

License from Mid-Atlantic BioTherapeutics for IMT504 broadens Scope of Initial License Beyond Treatment...

October 7, 2021, 10:20 am

Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine

License from Mid-Atlantic BioTherapeutics for IMT504 broadens Scope of Initial License Beyond Treatment...

October 7, 2021, 10:20 am

Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine

License from Mid-Atlantic BioTherapeutics for IMT504 broadens Scope of Initial License Beyond Treatment...

October 7, 2021, 10:20 am

Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine

BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the...

October 7, 2021, 9:45 am

Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine

BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the...

October 7, 2021, 9:45 am

Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine

BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the...

October 7, 2021, 9:45 am


Search within

Pages Search Results: